Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection  by Ramezani, Amitis et al.
Rate of YMDD motif mutants in lamivudine-
untreated Iranian patients with chronic
hepatitis B virus infection
Amitis Ramezani a,b, Ali Akbar Velayati c, Mohammad Reza Hasanjani
Roshan d, Latif Gachkar b, Mohammad Banifazl e, Hossein Keyvani f,
Arezoo Aghakhani a,*
International Journal of Infectious Diseases (2008) 12, 252—255
http://intl.elsevierhealth.com/journals/ijidaClinical Research Department, Pasteur Institute of Iran, No. 69, Pasteur Ave., Tehran, Iran
b Infectious Diseases Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
cMasih Daneshvari Hospital, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
dBabol University of Medical Sciences, Babol, Iran
e Iranian Society for the Support of Patients with Infectious Diseases, Tehran, Iran
fKeyvan Virology Laboratory, Tehran, Iran
Received 22 April 2007; received in revised form 31 July 2007; accepted 22 August 2007
Corresponding Editor: Jane Zuckerman, London, UKKEYWORDS
Chronic hepatitis B;
Lamivudine;
PCR-RFLP;
YMDD motif mutants
Summary
Background: Lamivudine is used for the treatment of chronic hepatitis B patients. Recent studies
show that the YMDDmotif mutants (resistant hepatitis B virus) occur as natural genome variability
in lamivudine-untreated chronic hepatitis B patients. In this study we aimed to determine the
rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran.
Patients and methods: A total of 77 chronic hepatitis B patients who had not been treated with
lamivudine were included in the study. Serum samples from patients were tested by polymerase
chain reaction-restriction fragment length polymorphism (PCR-RFLP) for detection of YMDDmotif
mutants. All patients were also tested for liver enzymes, anti-HCV, HBeAg, and anti-HBe.
Results: Of the77patients enrolled in the study, 73%weremale and27%were female.MeanALTand
AST levels were 124.4  73.4 and 103.1  81 IU/l, respectively. HBeAgwas positive in 40% and anti-
HBe in 60% of the patients. Anti-HCV was negative in all of them. YMDD motif mutants were
not detected in any of the patients despite the liver enzyme levels and the presence of HBeAg or
anti-HBe.
Conclusion: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated
patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian
lamivudine-untreated chronic hepatitis B patients.
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YMDD mutants in untreated chronic hepatitis B patients 253Introduction
Hepatitis B is one of the most common infectious diseases in
the world. It is estimated that more than 300 million people
worldwide have chronic hepatitis B virus (HBV) infection and
that 10% of these patients will die as a direct consequence of
persistent viral infection.1 The global prevalence of chronic
HBV infection varies widely, from high (>8%), e.g., in Africa,
Asia, and the Western Pacific, to intermediate (2—7%), e.g.,
in Southern and Eastern Europe, to low (<2%), e.g., in
Western Europe, North America, and Australia.2
Nucleoside analogue therapy allows the safe, long-term
suppression of HBV, and its usemarks amajor milestone in the
treatment of chronic hepatitis B. Lamivudine, the first of
these agents approved worldwide, effectively suppresses
viral replication, reduces disease activity, improves liver
histology, and delays clinical progression.3,4 However, the
development of lamivudine-resistant mutations occurs in
14—32% of patients after 1 year of therapy.5,6 The longer
the treatment is continued, the more frequently resistance is
seen (65% at 5 years).7 Lamivudine-resistant HBV is asso-
ciated with mutations of the YMDD motif in the polymerase
gene. The key mutations are the substitutions of methionine
at the rtM204 (domain C) to either isoleucine (rtM204I, YIDD
variant) or valine (rtM204V, YVDD variant).8,9 The rtM204V
variant is almost always accompanied by an additional
rtL180M mutation in the domain B.10—12
HBV mutants with mutations in the YMDD motif of viral
polymerase have been described in patients infected with
HBV who have not received lamivudine therapy.13,14 Also,
cases of early emergence of mutants have been described,
suggesting that mutations conferring lamivudine resistance
were already present in the liver of these patients before
starting therapy. This would mean that these mutant strains
circulate among the population, so that a certain proportion
of HBV carriers or chronic hepatitis B patients from a given
geographical area might have any of them.15
The presence of a drug-resistant HBV variant before
treatment could be a reason for selecting an alternative drug
for therapy. Thus, routine testing for mutations involved in
antiviral drug resistance might be useful for candidate
patients.15 To judge whether this activity would be appro-
priate, however, prior knowledge of the prevalence of these
variants among the HBV infected population is required. This
study was performed to determine the rate of YMDD motif
mutants in lamivudine-untreated chronic hepatitis B patients
in Iran.
Patients and methods
In this cross-sectional study, 77 chronic hepatitis B patients
were tested for the presence of YMDD motif mutants. One or
both of the following inclusion criteria had to be met: (1)
HBsAg persistence for more than six months with liver
enzymes more than 1.5 times the upper limit of normal;
(2) HBsAg persistence for more than six months and liver
biopsy with signs of chronic hepatitis confirmed by a pathol-
ogist according to the Knodell necroinflammatory score sys-
tem.16 None of the patients had been treated with antiviral
medications including lamivudine.
Blood samples were collected from the patients and the
serum stored at 70 8C. All samples were tested by poly-merase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP) for detection of YMDD motif
mutants. Simultaneously, liver enzymes (ALT and AST) were
also determined in all of them. Samples were also tested for
hepatitis C antibody (anti-HCV), hepatitis B e antigen
(HBeAg), and hepatitis B e antibody (anti-HBe) by ELISA.
The commercial ELISA kits used were: anti-HCV, Bio-Rad
Laboratories, Segrate, Italy; HBeAg and anti-HBe, Radim,
Barcelona, Spain. All assay protocols, cut-offs, and result
interpretations were carried out according to the manufac-
turers’ instructions.
PCR-RFLP
HBV variants at M552 (nucleotides 741 or 743) were detected
by PCR-RFLP. Three separate PCR assays were used to amplify
three fragments around position 552 of the polymerase gene.
A 274-bp fragment was amplified using the primer pair P2 (50-
AAA CCT TCG GAC GGA AAC TGC-30) and P4 (50-CTG GAT CCA
GGG TTTAAATGTATA CCC-30), and the fragment was digested
with FokI restriction enzyme, which cuts the sequence of the
wild type YMDD and YVDD variant into 143 bp, 100 bp, and
31 bp and the sequence of the YIDD variant into 243 bp and
31 bp. The 31-bp fragment was not related to the identifica-
tion of YMDD variants. A 181-bp fragment was amplified using
the primer pair P5 (50-TGG AAT TCA CCT GTA TTC CCA TCC
CAT-30) and P6 (50-CAG ACT TGG CCC CCA ATA CCA CAT CGT
GCA-30, which introduces an Alw441 site only into the YVDD
mutant product), and the fragment was digested with Alw441
restriction enzyme, which cuts the sequence of the YVDD
variant into 158 bp and 23 bp. A 138-bp fragment was ampli-
fied using the primer pair P4 (50-CTG GAT CCA GGG TTT AAA
TGT ATA CCC-30) and P3 (50-TTT CCC CCA CTG TTT GGC TTT
CAG TAA TAT-30, which introduces an SspI site only into the
YIDD mutant product), and the fragment was digested with
SspI restriction enzyme, which cuts the sequence of the YIDD
variant into 109 bp and 29 bp. Restriction enzyme SspI and
Alw441 cutting sites were introduced into primers P3 and P6,
respectively.
For DNA extraction, 100 ml of each patient’s serum was
mixed with 150 ml of TES buffer containing 10% sodium
dodecyl sulfate and proteinase K, and then incubated at
60 8C for 1 hour. After digestion with proteinase K, DNA
was extracted by phenol/chloroform/isoamyl alcohol.
Extracted DNA was precipitated with absolute ethanol, then
washed with 70% ethanol and dissolved in 30 ml of TE buffer
(10 mM Tris-HCl, pH 8.0; 1 mM EDTA). The DNA was used for
three amplification reactions of PCR. Final concentrations in
the three PCR reactions were as follows: 20 mmol Tris (pH
8.3), 0.2 mmol KCl, 1.5 mmol MgCl2, 18 mmol NaCl, 0.2 mmol
dNTPS, 0.5 mmol each primer, and 2.5 U Taq polymerase per
50 ml of reaction mixture. The amplification conditions in the
three PCR reactions all included initial denaturation at 94 8C
for 3 minutes, 35 cycles of amplification with denaturation at
94 8C for 35 seconds, primer annealing at 56 8C for 50 sec-
onds, extension of primer at 72 8C for 50 seconds, followed by
a final extension at 72 8C for 5 minutes.
After amplification, aliquots of the product DNA of the
three PCR reactions were digested with three enzymes,
respectively, according to the manufacture’s specifications
(Shanghai Biology Project Technology Company). The diges-
tion reactions included 15 ml amplified HBV DNA, 10 U
254 A. Ramezani et al.enzyme, 10 restriction enzyme digestion buffer 2 ml, and
3 ml sterile ddH2O in a sterile Eppendorf tube. The tube was
spun at 500 rpm for 3 seconds. The SspI and Alw441 enzyme
reaction mixtures were incubated in a 37 8C water bath for
16 hours. The FokI enzyme reaction mixture was incubated
in a 55 8C water bath for 3 hours .The results of PCR-RFLP
were analyzed by 8.4% polypropylene acidemide gel electro-
phoresis.17 The detection limit of the assay was 10 000 copies
per ml.
Statistical analysis
Chi-square and t2 tests were used with the SPSS 11.5 program
for statistical analysis. Data are presented as means  stan-
standard deviations or, when indicated, as absolute number
and percentage. A p value of <0.05 was considered signifi-
cant.
Results
A total of 77 patients were enrolled in this study; 73% of them
weremale and 27% were female and they were aged between
11 and 50 years (mean 27.4  9.3). Chronic hepatitis B was
diagnosed in patients based on HBsAg persistence for more
than six months with liver enzymes more than 1.5 times the
upper limit of normal and/or HBsAg persistence formore than
six months with liver biopsy signs of chronic hepatitis con-
firmed by a pathologist. None of the patients had been
treated with antiviral medications including lamivudine. In
these patients ALT, AST, HBeAg, anti-HBe, and anti-HCV tests
and detection of YMDD motif mutants were done simulta-
neously.
The patients’ ALT levels were between 28 and 500 IU/l
(mean 124.4  73.4) and AST levels were between 22 and
500 IU/l (mean 103.1  81). HBeAg and anti-HBe were posi-
tive in 40% and 60% of the patients, respectively. Anti-HCV
was negative in all of them.
In 46 patients, the diagnosis of chronic hepatitis B was
based on the liver biopsy. The liver biopsy scores were
between 2 and 13 (mean 5.9  2.4), grade (activity) was
between 1 and 9 (mean 3.6  2.3), and stage (fibrosis)
between 0 and 3 (mean 1.2  1.1) according to the Knodell
necroinflammatory score system.16
PCR was ‘not determined’ in 48% (37/77) of the patients
and was ‘sensitive’ in 52% (40/77) of them. No YMDD motif
mutations (0) were detected in chronic hepatitis B patients
by RFLP.
Discussion
HBV is one of the most common infectious diseases in the
world. HBV genotypes represent naturally occurring strains of
HBV that have evolved over the years and reflect the geo-
graphical distribution of HBV throughout the world. Geno-
type D is most often found in Southern Europe, parts of
Central Asia, India, Africa, and the Middle East.18 In Iran,
genotype D is the only detected type found in all HBV infected
patients.19
Lamivudine is an antiviral drug approved for the treat-
ment of chronic hepatitis B.15 However, the emergence of
viral mutants resistant to lamivudine is the main concernwith this treatment. The cause of lamivudine-resistant HBV
was revealed to be the amino acid substitution from leucine
to methionine at codon 180 of the B domain (rtL180M) and
amino acid substitutions of the YMDD motif from methionine
to valine or isoleucine at codon 204 of the C domain (rtM204V
or rtM204I) of the reverse transcriptase (rt) region of the
polymerase gene.20—24
Data supporting the natural occurrence of lamivudine-
resistant strains among the population of chronic HBV car-
riers have been reported recently from Japan and
France.23,25 Some researchers have found the YMDD muta-
tional strains in the serum of cases with chronic hepatitis B
who did not receive lamivudine treatment.14,23,26 Yan et al.
showed that 19 out of 110 chronic hepatitis B untreated cases
had YMDD mutations.26 The results from a study in Spain
indicate that the prevalence of these mutants is about 4%
among Spanish chronic HBV carriers.15 In a study in Japan,
mutations were detected in five out of 18 untreated chronic
hepatitis B patients.23 In addition, Zhang et al. found that
26.2% of chronic hepatitis B cases had YMDD mutations by
genetic chip determination.27 Matsuda et al. reported that a
few chronic hepatitis B cases not treated with lamivudine had
YMDD mutations.13 Naturally occurring YMDD motif variants
were detected at a high rate in a group of lamivudine-
untreated inactive HBV carriers in Turkey.28 Other studies
have not reported YMDDmutations in non-lamivudine treated
hepatitis B patients.22 In a study in China, the YMDD mutants
were not detected in any of the five patients before lami-
vudine treatment.29
Kobayashi et al. found that anti-HBe was positive in all
patients with YMDD mutations,23 and Ye et al. also found that
anti-HBe was positive in most patients with YMDD mutations
and considered that YMDD mutations might occur more easily
if mutations took place in the pre-c zone.30 In a study in
China, the incidence rate of YMDD mutations was 27.1% in
patients with positive HBeAg and 26.7% in patients with
negative HBeAg and positive anti-HBe. There was no signifi-
cant difference between the two groups.31 Lee et al.
detected YMDD mutants in eight of 12 HBeAg-positive
patients and eight of 16 HBeAg-negative patients before
lamivudine treatment.12
In our study, the YMDDmotif mutants were not detected in
any of the chronic hepatitis B patients before lamivudine
treatment despite the liver enzyme levels and the presence
of HBeAg or anti-HBe. These results do not accord with some
studies20,24 but are in agreement with others.22,29 This low
rate may be explained by epidemiological and geographic
variations and study conditions such as the number of
patients and the method used for detecting the YMDD motif
mutants. YMDD mutants have significantly low replication
ability. It is thought that the naturally occurring YMDD
mutants make up only a very small proportion of the total
HBV, and very sensitive investigative tools are required to
detect them.32 RFLP often leaves out those samples with
mixed virus populations and a low-component virus popula-
tion, and is suited only for mono-infection.33 Further studies
are needed to determine exactly the rate of YMDD motif
mutants in lamivudine-untreated chronic hepatitis B
patients.
In conclusion, although the natural occurrence of YMDD
motif mutants in lamivudine-untreated patients with chronic
hepatitis B infection has been reported, these mutants were
YMDD mutants in untreated chronic hepatitis B patients 255not detected in Iranian lamivudine-untreated chronic hepa-
titis B patients. Further studies with more samples and more
sensitive investigative tools should be conducted to deter-
mine this rate exactly.
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